MBOT vs. NXGL, SSKN, PETV, GCTK, BTCY, TTOO, PSTV, NURO, MHUA, and OSA
Should you be buying Microbot Medical stock or one of its competitors? The main competitors of Microbot Medical include NEXGEL (NXGL), STRATA Skin Sciences (SSKN), PetVivo (PETV), GlucoTrack (GCTK), Biotricity (BTCY), T2 Biosystems (TTOO), Plus Therapeutics (PSTV), NeuroMetrix (NURO), Meihua International Medical Technologies (MHUA), and ProSomnus (OSA). These companies are all part of the "surgical & medical instruments" industry.
NEXGEL (NASDAQ:NXGL) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.
In the previous week, NEXGEL had 4 more articles in the media than Microbot Medical. MarketBeat recorded 7 mentions for NEXGEL and 3 mentions for Microbot Medical. NEXGEL's average media sentiment score of 0.56 beat Microbot Medical's score of 0.35 indicating that Microbot Medical is being referred to more favorably in the news media.
2.2% of NEXGEL shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 27.2% of NEXGEL shares are held by insiders. Comparatively, 10.6% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
NEXGEL has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.
Microbot Medical has a consensus price target of $7.00, suggesting a potential upside of 644.60%. Given NEXGEL's higher probable upside, analysts clearly believe Microbot Medical is more favorable than NEXGEL.
Microbot Medical received 345 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Microbot Medical has a net margin of 0.00% compared to Microbot Medical's net margin of -67.48%. Microbot Medical's return on equity of -54.71% beat NEXGEL's return on equity.
NEXGEL has higher revenue and earnings than Microbot Medical. NEXGEL is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Microbot Medical beats NEXGEL on 9 of the 16 factors compared between the two stocks.
Get Microbot Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Microbot Medical Competitors List
Related Companies and Tools
